Scientists have identified a significant number of potential targets for a malaria vaccine by analyzing peptides presented on infected human cells. This research, utilizing immunopeptidomics, has uncovered 453 unique peptides derived from malaria parasites that are recognized by CD8+ T cells. These peptides map to 166 different parasite proteins, with 75 identified as housekeeping proteins crucial for the parasite’s survival across multiple life stages and conserved between major malaria species, Plasmodium falciparum and Plasmodium vivax.
Identifying Potential Vaccine Targets
The study focused on reticulocytes infected with Plasmodium vivax, the primary malaria species in the Americas and Asia. These reticulocytes retain the ability for host protein synthesis and express human leukocyte antigen class I (HLA-I), which allows them to be recognized and targeted by CD8+ T cells. The identified peptides were presented by various HLA alleles, including HLA-A, HLA-B, HLA-C, and the non-classical HLA-E allele, in different individuals and sometimes by distinct HLA types.
A key finding is that many of these newly identified antigens are highly conserved, existing in both Plasmodium vivax and Plasmodium falciparum, the most prevalent human malaria parasite in Africa. This conservation suggests that a vaccine targeting these antigens could offer protection against multiple malaria species.
Validation and Promising Results
The antigenicity of these newly discovered epitopes was confirmed using samples from individuals infected with either Plasmodium vivax or Plasmodium falciparum. Further validation came from studies involving non-human primates, where T cell responses to several of these antigens were observed in blood and liver tissues following infection or immunization with weakened parasites. Notably, two of the identified antigens were shown to induce protective CD8+ T cell-mediated immunity in rodent models.
These findings indicate that the identified antigens hold potential for developing a malaria vaccine that is effective across different stages of the parasite’s life cycle and against various Plasmodium species. The lack of validated T cell epitope targets has been a significant hurdle in malaria vaccine development, and this discovery offers a promising path forward.
The research involved analyzing peptides presented by HLA-I on infected reticulocytes, leading to the identification of antigens that are not only conserved but also capable of eliciting immune responses in different species and in various parts of the body. The validation in non-human primates and the protective effect observed in rodents underscore the potential of these antigens for future vaccine strategies against malaria.
Steve Lopez is the Editorial Page Editor for News Raise. He covers Health. He has won more than a dozen national journalism awards for his reporting and column writing at seven newspapers and four news magazines.
